EBRO 2017

Follow-up

• Median follow-up for all patients 13.4 years

– Cases (BRCA1/2 mutation carriers): 13.9 years

[3-19.2]

– Familial cases (Non carriers)

13.4 years [2.3-22.5]

– Controls:

13 years

[2.7-24.8]